# ScoreItem: Doen√ßa renal (DRC, nefrite, nefr√≥tica, lit√≠ase, ITU repeti√ß√£o)

**ID:** `c77cedd3-2800-731d-88cb-2ac2422f8e86`
**FullName:** Doen√ßa renal (DRC, nefrite, nefr√≥tica, lit√≠ase, ITU repeti√ß√£o) (Hist√≥rico Familiar de Doen√ßas - Parentes pr√≥ximos (pais, irm√£os, tios, av√≥s, filhos, netos))

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 8 artigos
- Avg Similarity: 0.518

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-731d-88cb-2ac2422f8e86`.**

```json
{
  "score_item_id": "c77cedd3-2800-731d-88cb-2ac2422f8e86",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Doen√ßa renal (DRC, nefrite, nefr√≥tica, lit√≠ase, ITU repeti√ß√£o) (Hist√≥rico Familiar de Doen√ßas - Parentes pr√≥ximos (pais, irm√£os, tios, av√≥s, filhos, netos))

**30 chunks de 8 artigos (avg similarity: 0.518)**

### Chunk 1/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.569

specickidneyfunctionofglomerularltration.Usethemoregeneralterm‚Äúkidneyfunction(s)‚Äùwhendealingwiththetotalityoffunctionsofthekidney.
PhysicalexamNephrotoxicmedicationsSymptoms and signsof urinary tractabnormalitiesSymptoms and signsof systemic diseasesLaboratory tests, imaging, and tissue sample, such as:‚Ä¢ Urinalysis and urine sediment‚Ä¢ Urine albumin-to-creatinine ratio‚Ä¢ Serologic tests
‚Ä¢ Ultrasound‚Ä¢ Kidney biopsy‚Ä¢ Genetic testingMedicalhistorySocial andenvironmentalhistoryObtain careful family historyfor possible genetic causes,including family pedigree for CKD
Figure8|Evaluationofcauseofchronickidneydisease(CKD).

---

### Chunk 2/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.559

k forrecurrence afterkidney transplantationConditions for whichgenetic testing isrelevant for reproductivecounselingExamples:‚Ä¢ GLA (Fabry)‚Ä¢ AGXT (primaryhyperoxaluria (PH))‚Ä¢ CoQ10 genes (SRNS)‚Ä¢ CTNS (cystinosis)‚Ä¢ Tubulopathies(Na+, K+ etc.)Conditions amenable to nonspecific renoprotective strategiesExample:‚Ä¢ COL4A3/4/5 (Alport)and RAAS blockadeExample:
‚Ä¢ Glomerular diseasedue to mutations inAlport genes(COL4A3/4/5)Examples:‚Ä¢ (CFH/CFI/C3...): aHUS‚Ä¢ (AGXT, GRHPR, HOGA): primary hyperoxaluria (PH)
‚Ä¢ Adenine phosphoribo-  syltransferase deficiency (APRT)Conditions amenable to specific screening for extrarenal manifestationsExamples:‚Ä¢ HNF1B: diabetes‚Ä¢ PKD1/PKD2(ADPKD): intracranialaneurysms ‚Ä¢ FLCN: renal cellcarcinoma, etc.Example:
‚Ä¢ Prenatal/preimplantationdiagnosis
Figure9|Actionablegenesinkidneydisease.Actionabilityreferstothepotentialforgeneticrestresultstoleadtospecicclinicalactionsfrompreventionortreatmentofacondition,supportedbyrecommendationsbasedonevide

---

### Chunk 3/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.548

ropriatetreatment.KeyinformationBalanceofbenetsandharms.Thebenetsofkidneybi-opsyintermsofdiagnosis,prognosis,andplanningappro-
priatetreatmentforboththepersonwithCKDandhealthcare
PhysicalexamNephrotoxicmedicationsSymptoms and signsof urinary tractabnormalitiesSymptoms and signsof systemic diseasesLaboratory tests, imaging, and tissue sample, such as:‚Ä¢ Urinalysis and urine sediment‚Ä¢ Urine albumin-to-creatinine ratio‚Ä¢ Serologic tests
‚Ä¢ Ultrasound‚Ä¢ Kidney biopsy‚Ä¢ Genetic testingMedicalhistorySocial andenvironmentalhistoryObtain careful family historyfor possible genetic causes,including family pedigree for CKD
Figure8|Evaluationofcauseofchronickidneydisease(CKD).

---

### Chunk 4/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.548

RifCKDisdeemedlikelyduetopresenceofotherclinicalindicators.1.1.4Evaluationofcause
PracticePoint1.1.4.1:EstablishthecauseofCKDusingclinicalcontext,personalandfamilyhistory,socialandenvi-ronmentalfactors,medications,physicalexamination,laboratorymeasures,imaging,andgeneticandpathologicdiagnosis(Figure8).
www.kidney-international.orgsummaryofrecommendationstatementsandpracticepointsKidneyInternational(2024)105(Suppl4S),S117‚ÄìS314S149

PracticePoint1.1.4.2:Useteststoestablishacausebasedonresourcesavailable(Table622,98-100).Recommendation1.1.4.1:Wesuggestperformingakidneybiopsyasanacceptable,safe,diagnostictesttoevaluatecauseandguidetreatmentdecisionswhenclinicallyappropriate(2D).1.2EvaluationofGFR1.2.1OtherfunctionsofkidneysbesidesGFR
PracticePoint1.2.1.1:Usetheterm‚ÄúGFR‚Äùwhenreferringtothespecickidneyfunctionofglomerularltration.Usethemoregeneralterm‚Äúkidneyfunction(s)‚Äùwhendealingwiththetotalityoffunctionsofthekidney.

---

### Chunk 5/30
**Article:** Fisiologia e Bioqu√≠mica do Sistema Imune II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.543

olicitar e registrar par√¢metros essenciais (PCR-us, VHS); calcular √≠ndices estim√°veis (HGI, TAIG); considerar complementares (TNF-Œ±, IL-6, GPx, MDA, antioxidantes totais).
- [ ] 11. Monitorar trimestralmente HbA1c, glicemia de jejum e HGI; estabelecer metas individuais (ex.: reduzir de 6,1 para ~5,5; longo prazo ~5,3).
- [ ] 12. Calcular TG/HDL e integrar com lipidograma/SREBP1c/2; evitar combina√ß√£o de gordura saturada com a√ß√∫car e excesso de saturadas em m√∫ltiplas refei√ß√µes.
- [ ] 13. Avaliar ferro, ferritina, transferrina e satura√ß√£o (20‚Äì50%; evitar <20%); interpretar com hepcidina/SREBP1c e quadro inflamat√≥rio.
- [ ] 14. Medir TNF-Œ± (<8,1) e IL-6 (<3,4) para acompanhar atividade inflamat√≥ria; relacionar com obesidade inflamada.
- [ ] 15. Calcular HOMA-Œ≤ (167‚Äì175) e HOMA-IR (<2,15); buscar glicemia 60‚Äì90 e insulina ~6‚Äì7.
- [ ] 16. Monitorar homociste√≠na (<7,9) e PCR; usar PCR-us; documentar crises (PCR >1.000) e conduzir manejo apropriado.
- [ ] 17.

---

### Chunk 6/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.531

arltrationrate[eGFRcr-cys])(1B).1.1.3EvaluationofchronicityPracticePoint1.1.3.1:Proofofchronicity(durationofaminimumof3months)canbeestablishedby:(i)reviewofpastmeasurements/estimationsofGFR;(ii)reviewofpastmeasurementsofalbuminuriaorproteinuriaandurinemicroscopicexaminations;(iii)imagingndingssuchasreducedkidneysizeandreductionincorticalthickness;(iv)kidneypathologicalndingssuchasbrosisandatrophy;(v)medicalhistory,especiallyconditionsknowntocauseorcontributetoCKD;(vi)repeatmeasurementswithinandbeyondthe3-monthpoint.PracticePoint1.1.3.2:DonotassumechronicitybaseduponasingleabnormallevelforeGFRandACR,asthendingcouldbetheresultofarecentacutekidneyinjury(AKI)eventoracutekidneydisease(AKD).PracticePoint1.1.3.3:ConsiderinitiationoftreatmentsforCKDatrstpresentationofdecreasedGFRorelevatedACRifCKDisdeemedlikelyduetopresenceofotherclinicalindicators.1.1.4Evaluationofcause
PracticePoint1.1.4.1:EstablishthecauseofCKDusingclinicalcontext,personalandfamilyhistory,socialandenvi-ronmentalfactor

---

### Chunk 7/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.529

anginglistof‚Äúatrisk‚Äùgroups.27TestingforCKDwithoutregardtoagegeneratescontro-versy.Thoseinolderagegroupsexperiencethegreatest
burdenofCKDandarealsoatthehighestriskforcardio-
vascularcomplications.Aswithotherdetectionprogramslike
cancerdetection,CKDdetectioneffortsshouldbeindividu-
alizedbasedontheperson‚Äôsgoalsofcareandsuitabilityfortreatment.PracticePoint1.1.1.2:Followingincidentaldetectionofelevatedurinaryalbumin-to-creatinineratio(ACR),he-
maturia,orlowestimatedGFR(eGFR),repeatteststo
conrmpresenceofCKD.ThereisknownbiologicalandanalyticalvariabilityinSCrandinurinealbuminorurineproteinnotrelatedtotheir
propertiesasmarkersofkidneydisease.Inpeoplewithout
riskfactorsforCKD,thereisalowpretestprobabilityforCKD.Thus,anyunexpectedresultsshouldbeveriedbeforediagnosingapersonashavingCKD.InpeoplewithriskfactorsforCKD,thereisahigherprobabilitythattheperson
doeshaveCKDevenwithanunexpectednding.Subsequenttestingshouldbeperformedtoconrmthediagnosisandtocompletetheevaluation,asisrequired.Ti

---

### Chunk 8/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** introduction | **Similarity:** 0.529

24)105(Suppl4S),S117‚ÄìS314

SpecialconsiderationsPediatricconsiderations.Newbornswhoclearlyhavekidneydisease(e.g.,severecongenitalmalformationsofthekidneyandurinarytract)donotneedtowait3monthstoconrmCKD.1.1.4EvaluationofcausePracticePoint1.1.4.1:EstablishthecauseofCKDusing
clinicalcontext,personalandfamilyhistory,socialand
environmentalfactors,medications,physicalexamination,
laboratorymeasures,imaging,andgeneticandpathologic
diagnosis(Figure8).PracticePoint1.1.4.2:Useteststoestablishacausebased
onresourcesavailable(Table622,98-100).Inevaluationofcause,healthcareprovidersshouldselectspecicdiagnostictestsbasedonthepretestprobabilityofaspecicdiagnosisinformedbyclinicalpresentation.Identica-tionofcauseconfersbenetfortargetingtherapytoslowpro-gressiontokidneyfailure,understandingcontributingfactors,
andprognosis.Inaddition,identicationofcausecanhelppeoplecommunicateinformationaboutageneticorfamilial
causetorelatives,improveunderstandingoftheirconditioninthecontextofself-caremanageme

---

### Chunk 9/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.526

eycanprovideinformationtoidentifycause,facilitateprognostication,andinformtreatmentstrategies.SpecialconsiderationsPediatricconsiderations.Childrenandyoungpeoplewithkidneyfailurearemorelikelytohaveageneticcauseoftheir
diseasethanadults.Insomehealthcaresettings,genetictestingmaybepursuedrst,obviatingtheneedforkidneybiopsyandtheassociatedrisks,whichmaybedifferentin
childrenthanadults.1.2EvaluationofGFRThekidneyhasmanyfunctions,includingexcretory,endo-
crine,andmetabolicfunctions.GFRisonecomponentof
Centers of expertise(multidisciplinary teams)All nephrologyclinicsConnections with geneticistsand genetic counselorsNumber of nephrologistsClinic typeKnowledge levelHighMediumBasicAs manyas possibleFewAllSource of knowledgeAdvanced training andsubspecialties and extensiveclinical experienceCME courses, workshopsand heuristically basedMedical school/fellowships/licensing
Figure10|Proposedorganizationforimplementinggeneticsinnephrology.Withinahealthsystem,multiplecentertypes,providerspecialties

---

### Chunk 10/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.525

eoplewithriskfactorsforCKD,thereisahigherprobabilitythattheperson
doeshaveCKDevenwithanunexpectednding.Subsequenttestingshouldbeperformedtoconrmthediagnosisandtocompletetheevaluation,asisrequired.Timingoftherepeat
sampleshouldbedeterminedbasedonclinicalsetting
includingriskfactorsforCKDaswellasconcernforAKI/AKD.Hematuriaiscommonandassociatedwithriskforsub-sequentdevelopmentofCKD.65Thereareseveralcausesof
chapter1www.kidney-international.orgS170KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314

transienthematuria.Persistenthematuriamayindicateglomerulardisease,otherkidneydiseases,orurologic
diseaseincludinggenitourinarymalignancy.Thus,persistenthematuriashouldpromptfurtherinvestigation.66,67SpecialconsiderationsPediatricconsiderations.Peoplewhoarebornpreterm,especiallyifalsosmallforgestationalage,areatincreasedrisk
forCKDandkidneyfailure.Thisislargelyrelatedtodecreasednephronnumber.68‚Äì70AdditionalinsultsafterbirthsuchasneonatalAKIandchildhoodobesitycanfurtherin-
creasetheriskofCKD.7

---

### Chunk 11/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIX (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.520

g/kg) e pr√°tica de exerc√≠cios de resist√™ncia para preservar massa muscular.
- [ ] 3. Todos os profissionais: Em doen√ßas cr√¥nicas sem causa org√¢nica clara ou com m√° resposta ao tratamento, investigar ativamente traumas de inf√¢ncia, estresse cr√¥nico e quest√µes emocionais n√£o resolvidas como poss√≠vel "causa primeira".
- [ ] 4. Terapeutas e psic√≥logos: Adotar "terapia de precis√£o", utilizando m√∫ltiplas ferramentas e combinando diferentes abordagens terap√™uticas para personalizar o tratamento e focar em resultados mensur√°veis, em vez de seguir uma √∫nica linha te√≥rica por longos per√≠odos.
- [ ] 5. Estudo pessoal: Pesquisar o conceito de "causa primeira" de Arist√≥teles para aprofundar a l√≥gica de buscar a origem dos problemas.
- [ ] 6. Estudo pessoal: Ler o livro de Bruce Lipton sobre a conex√£o entre mente e doen√ßas f√≠sicas.

---

## SOAP

> Data e Hora: 2025-11-17 16:33:53
> Paciente: 
> Diagn√≥stico:

## Hist√≥rico do Diagn√≥stico:
1. Hist√≥rico M√©dico: 
2.

---

### Chunk 12/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.518

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 13/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.517

e-basedequations.TransplInt.2012;25:527‚Äì536.162.JanusN,Launay-VacherV,ByloosE,etal.CancerandrenalinsufciencyresultsoftheBIRMAstudy.BrJCancer.2010;103:1815‚Äì1821.163.Launay-VacherV,JanusN,DerayG.Renalinsufciencyandcancertreatments.ESMOOpen.2016;1:e000091.164.NaSY,SungJY,ChangJH,etal.Chronickidneydiseaseincancerpatients:anindependentpredictorofcancer-specicmortality.AmJNephrol.2011;33:121‚Äì130.165.RosnerMH,JhaveriKD,McMahonBA,etal.Onconephrology:the
intersectionsbetweenthekidneyandcancer.CACancerJClin.2021;71:47‚Äì77.166.SoveriI,BergUB,BjorkJ,etal.MeasuringGFR:asystematicreview.AmJKidneyDis.2014;64:411‚Äì424.167.WhiteCA,AkbariA,AllenC,etal.Simultaneousglomerularltrationratedeterminationusinginulin,iohexol,and99mTc-DTPAdemonstratestheneedforcustomizedmeasurementprotocols.KidneyInt.2021;99:957‚Äì966.168.XieP,HuangJM,LiuXM,etal.(99m)Tc-DTPArenaldynamicimaging
methodmaybeunsuitabletobeusedasthereferencemethodin
investigatingthevalidityofCDK-EPIequationfordetermining
glomerularltrati

---

### Chunk 14/30
**Article:** Fisiologia e Bioqu√≠mica do Sistema Imune II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.516

nsulina ideal ~6‚Äì7 (at√© 8 em inflama√ß√£o).
- Homociste√≠na: <7,9; correlaciona com PCR; polimorfismos FUT/MTHFR podem elev√°-la.
- PCR: desej√°vel <1; risco m√©dio 1‚Äì3; alto >3; casos extremos >1.000 em crise; usar PCR-us para sensibilidade; VHS para trajet√≥ria da inflama√ß√£o.
### 12. Prefer√™ncias e filosofia de ciclo
- Estrat√©gias c√≠clicas (jejum, low carb, cetog√™nica limpa, exerc√≠cio em jejum) para treinar flexibilidade metab√≥lica e melhorar uso de corpos cet√¥nicos.
- Protocolos fundamentados em literatura (PubMed: ‚ÄúInflammation and Phytochemicals/Bioactive Compounds‚Äù) e pr√°tica cl√≠nica, com resultados consistentes.
### 13. Observa√ß√µes Motivacionais e Agradecimentos
- Inspira√ß√£o: ‚ÄúA const√¢ncia dos bons resultados que conduz os homens √† felicidade.‚Äù
- Agradecimentos e convite √† pr√°tica cont√≠nua; compromisso de apoio.
## ‚ùì Perguntas
- [Inserir Pergunta/Confus√£o]
## üìö Tarefas
- [ ] 1.

---

### Chunk 15/30
**Article:** Proteinuria (2023)
**Journal:** StatPearls Publishing
**Section:** abstract | **Similarity:** 0.515

Comprehensive clinical review of proteinuria covering definition, etiology, diagnosis, and management. Proteinuria serves as a marker of kidney damage assisting with diagnosis, prognosis, and therapy. Normal protein excretion is <150 mg/24 hours. Severity categories: nephritic range (150-3,500 mg/24h) and nephrotic range (>3,500 mg/24h). Urine dipstick provides semi-quantitative screening but has important limitations: false-positives with dehydration, alkaline urine, UTI; inability to detect positively charged proteins. UK CKD guidelines define significant proteinuria as UPCR >45 mg/mmol. Quantitative methods (spot UPCR preferred for convenience and reliability, or 24-hour urine collection for accuracy) are indicated when dipstick is positive or proteinuria >1 g/day is suspected. Early detection and quantification are crucial given associations with progressive renal disease and cardiovascular complications.

---

### Chunk 16/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.512

Figure9|Actionablegenesinkidneydisease.Actionabilityreferstothepotentialforgeneticrestresultstoleadtospecicclinicalactionsfrompreventionortreatmentofacondition,supportedbyrecommendationsbasedonevidence.ADPKD,autosomaldominantpolycystickidneydisease;aHUS,atypicalhemolyticuremicsyndrome,CKD,chronickidneydisease;RAAS,renin-angiotensin-aldosteronesystem,SRNS,
steroid-resistantnephroticsyndrome.ReproducedfromKDIGOConferenceParticipants.Geneticsinchronickidneydisease:conclusionsfroma
KidneyDisease:ImprovingGlobalOutcomes(KDIGO)ControversiesConference.KidneyInt.2022;101:1126‚Äì1141.100Copyright¬™2022,KidneyDisease:ImprovingGlobalOutcomes(KDIGO).PublishedbyElsevierInc.onbehalfoftheInternationalSocietyofNephrology.Thisisanopen
accessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).

---

### Chunk 17/30
**Article:** Automated urine sediment analyzers underestimate the severity of hematuria in glomerular diseases (2021)
**Journal:** Scientific Reports
**Section:** results | **Similarity:** 0.509

and digital imaging in one system: A multicenter performance evaluation of the cobas 6500 urine work area. Pract. Lab. Med. 17, e00139 (2019). 30. aller, T. R. & Wang, L. P. Evaluation of asymptomatic microscopic hematuria in adults. Am. Fam. Phys. 60, 1143¬ñ1152 (1999). 31. Palsson, R., Srivastava, A. & Waikar, S. S. Performance of the automated urinalysis in diagnosis of proliferative glomerulonephritis. Kidney Int. Rep. 4, 723¬ñ727 (2019). 32. Orlandi, P. F. et al. Hematuria as a risk factor for progression of chronic kidney disease and death: Findings from the chronic renal insuciency cohort (CRIC) study. BMC Nephrol. 19, 150 (2018). 33. Schulman, G. et al. Risk factors for progression of chronic kidney disease in the EPPIC trials and the eect of AST-120. Clin. Exp. Nephrol. 22, 299¬ñ308 (2018). 34. Mashitani, T. et al.

---

### Chunk 18/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.509

ta-analysis.ClinJAmSocNephrol.2022;17:1305‚Äì1315.193.vanEeghenSA,WiepjesCM,T‚ÄôSjoenG,etal.CystatinC-basedeGFRchangesduringgender-afrminghormonetherapyintransgenderindividuals.ClinJAmSocNephrol.2023;18:1545‚Äì1554.194.PierreC,MarzinkeM,AhmedSB,etal.AACC/NKFguidancedocumenton
improvingequityinchronickidneydiseasecare.JApplLabMed.2023;8:789‚Äì816.195.NgDK,FurthSL,WaradyBA,etal.Self-reportedrace,serumcreatinine,
cystatinC,andGFRinchildrenandyoungadultswithpediatrickidney
referenceswww.kidney-international.orgS298KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314

diseases:areportfromtheChronicKidneyDiseaseinChildren(CKiD)study.AmJKidneyDis.2022;80:174‚Äì185.e1.196.Luna-ZaizarH,Virgen-MontelongoM,Cortez-AlvarezCR,etal.Invitro
interferencebyacetaminophen,aspirin,andmetamizoleinserum
measurementsofglucose,urea,andcreatinine.ClinBiochem.2015;48:538‚Äì541.197.GreenbergN,RobertsWL,BachmannLM,etal.Specicitycharacteristicsof7commercialcreatininemeasurementproceduresbyenzymaticand
Jaffemethodpri

---

### Chunk 19/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.506

tNZJMed.1992;22:334‚Äì337.338.GilbertRE,AkdenizA,JerumsG.Detectionofmicroalbuminuriaindiabeticpatientsbyurinarydipstick.DiabetesResClinPract.1997;35:57‚Äì60.339.GrazianiMS,GambaroG,MantovaniL,etal.Diagnosticaccuracyofa
reagentstripforassessingurinaryalbuminexcretioninthegeneralpopulation.NephrolDialTransplant.2008;24:1490‚Äì1494.340.GuyM,NewallR,BorzomatoJ,etal.Useofarst-lineurineprotein-to-creatinineratiostriptestonrandomurinestoruleoutproteinuriain
patientswithchronickidneydisease.NephrolDialTransplant.2008;24:1189‚Äì1193.341.GuyM,NewallR,BorzomatoJ,etal.Diagnosticaccuracyoftheurinary
albumin:creatinineratiodeterminedbytheCLINITEKMicroalbuminandDCA2000√æfortherule-outofalbuminuriainchronickidneydisease.ClinChimActa.2008;399:54‚Äì58.342.HasslacherC,MullerP,SchlipfenbacherRL.ResultsofamulticentrestudyforthedeterminationofmicroalbuminuriawithMicral-Test.KlinischesLabor.1995;41:441‚Äì447.343.HodelNC,HamadA,ReitherK,etal.Comparisonoftwodifferent
semiquantitativeurinarydipsticktestswithal

---

### Chunk 20/30
**Article:** Resist√™ncia Insul√≠nica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.506

g/dL, HbA1c <5,7%.
- Pr√©-diabetes: jejum ‚â•100 e <126 mg/dL; 2h OGTT ‚â•140 e <200 mg/dL; HbA1c ‚â•5,7 e <6,5%; qualquer positividade confirma.
- Diabetes: jejum ‚â•126 mg/dL; 2h OGTT ‚â•200 mg/dL; glicemia aleat√≥ria ‚â•200 mg/dL com sintomas t√≠picos; HbA1c ‚â•6,5%.
- Repetir exames na aus√™ncia de correla√ß√£o cl√≠nica/sintomas antes de confirmar diagn√≥stico.
## S√≠ndrome Metab√≥lica: Defini√ß√£o e Crit√©rios
- Evolu√ß√£o da RI para s√≠ndrome metab√≥lica: hipertens√£o, DM2, risco cardiovascular (AVC/infarto).
- Defini√ß√£o pr√°tica: insufici√™ncia do tecido adiposo para lidar com supernutri√ß√£o.
- Crit√©rios (ATP III/IDF): circunfer√™ncia abdominal elevada (cortes vari√°veis por etnia), TG >150 mg/dL, HDL baixo, PA elevada, glicemia alterada; tratamento medicamentoso conta ponto.
- Condi√ß√µes associadas: SOP, lipodistrofias, hist√≥ria familiar, obesidade visceral.

---

### Chunk 21/30
**Article:** Fisiologia e Bioqu√≠mica do Sistema Imune II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.506

60 e 90
- [ ] Manter a insulina, o mais baixo poss√≠vel, 6, 7, estourando 8
- [ ] Avaliar a homociste√≠na, pois √© um marcador inflamat√≥rio importante
- [ ] Usar a prote√≠na C-reativa, associado com os n√≠veis de homociste√≠na
- [ ] Verificar os par√¢metros essenciais na avalia√ß√£o inflamat√≥ria
- [ ] Estimar o √≠ndice de glica√ß√£o e o √≠ndice TAIG, baseado nos resultados essenciais
- [ ] Complementar a avalia√ß√£o com TNF-alfa, IL-6, glutationa e malon de alde√≠do
### Tarefas para @
- [ ] Usar um concentrado de C8 ou um mix de C8 e C10, para estimular mais ainda o CP3 e as UCPs (prote√≠nas desacopladoras), diminuir a produ√ß√£o de esp√©cie reativa de oxig√™nio e aumentar a oxida√ß√£o de gordura @
- [ ] Incluir mioinositol, trans-resveratrol e epigalocatequina galato na formula√ß√£o, para diminuir os compostos de glica√ß√£o avan√ßada e a hemoglobina glicada @
- [ ] Fazer uma boa distribui√ß√£o de gordura e trabalhar os √°cidos graxos de cadeia curta, para obter o melhor benef√≠cio p

---

### Chunk 22/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.505

signicance[MGRS])98Presenceofpersistenthematuriaoralbuminuriaiscriticalindetermining
differentialdiagnosisGenetictestingAPOL1,COL4A3,COL4A4,COL4A5,NPHS1,UMOD,
HNF1B,PKD1,PKD2Evolvingasatoolfordiagnosis,increasedutilizationisexpected.
Recognitionthatgeneticcausesaremorecommonandmaypresent
withoutclassicfamilyhistory99,100ANCA,antineutrophilcytoplasmicantibody;APOL1,apolipoprotein1;COL4A,typeIVcollagenalphachain;CT,computedtomography;GBM,glomerularbasementmembrane;HNF1B,hepatocytenuclearfactor1B;MRI,magneticresonanceimaging;NPHS1,congenitalnephroticsyndrome;PKD1,polycystickidneydisease-1;PKD2,polycystickidneydisease-2;PLA2R,M-typephospholipaseA2receptor;UMOD,uromodulin.

---

### Chunk 23/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.502

lurinarytractdiseaseRecurrentkidneycalculiMultisystemdiseases/chronicinammatoryconditionsSystemiclupuserythematosus
Vasculitis
HIVIatrogenic(relatedtodrugtreatmentsandprocedures)Drug-inducednephrotoxicityandradiationnephritisFamilyhistoryorknowngeneticvariantassociatedwithCKDKidneyfailure,regardlessofidentiedcauseKidneydiseaserecognizedtobeassociatedwithgeneticabnormality(e.g.,PKD,APOL1-mediatedkidneydisease,andAlportsyndrome)GestationalconditionsPretermbirthSmallgestationalsizePre-eclampsia/eclampsiaOccupationalexposuresthatpromoteCKDriskCadmium,lead,andmercuryexposurePolycyclichydrocarbonsPesticidesAKD,acutekidneydisease;AKI,acutekidneyinjury;APOL1,apolipoproteinL1;CKD,chronickidneydisease;CKDu,chronickidneydiseaseofundeterminedorigin;PKD,polycystickidneydisease.

---

### Chunk 24/30
**Article:** Emagrecimento - Parte IV (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.501

 √µes cl√≠nicas da altera√ß√£o do microbioma; sinalizar n√≠vel de evid√™ncia.
> - Ajustes pr√°ticos: reduzir suplementos de BCAA, priorizar refei√ß√µes com fibras e vegetais.
### 10. Prote√≠na: metas, seguran√ßa renal e benef√≠cios
- Metas di√°rias: ~1,2‚Äì1,6 g/kg favorecem composi√ß√£o corporal, emagrecimento, envelhecimento saud√°vel e desempenho.
- A maioria n√£o atinge as metas por padr√£o rico em farinha e prote√≠na concentrada no almo√ßo/jantar.
- Seguran√ßa renal: em geral, dietas ricas em prote√≠na n√£o s√£o problema com fun√ß√£o renal preservada; insufici√™ncia renal grave requer cuidado especializado.
> Sugest√µes de IA
> - Quadro de convers√£o g/kg ‚Üí por√ß√µes/dia (ovos, carne, latic√≠nios).
> - Planilha de 1 dia com 3‚Äì4 distribui√ß√µes de prote√≠na (caf√©, almo√ßo, lanche, jantar).
> - Delimitar quem n√£o deve aumentar prote√≠na sem supervis√£o (est√°gios de DRC).
> - Checklist de triagem renal (eGFR, albumin√∫ria) antes de elevar prote√≠na.
### 11.

---

### Chunk 25/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.501

ersbladder,nuclearmedicinestudies,MRIAssesskidneystructure(i.e.,kidneyshape,size,symmetry,andevidenceofobstruction)forcysticdiseaseandreuxdisease.Evolvingroleofadditionaltechnologies(e.g.,3Dultrasound)KidneybiopsyUltrasound-guidedpercutaneousUsuallyexaminedbylightmicroscopy,immunouorescence,andelectronmicroscopy,and,insomesituations,mayincludemoleculardiagnostics
Usedforexactdiagnosis,planningtreatment,assessingactivityand
chronicityofdisease,andlikelihoodoftreatmentresponse;mayalsobe
usedtoassessgeneticdiseaseLaboratorytests:
serologic,urine
testsChemistryincludingacid-baseandelectrolytes,
serologictestssuchasanti-PLA2R,ANCA,anti-GBM
antibodies
Serum-freelightchains,serum,andurineprotein
electrophoresis/immunoxationUrinalysisandurinesedimentexaminationRefertoKDIGO2021ClinicalPracticeGuidelinefortheManagementofGlomerularDiseases22Increasingrecognitionoftheroleoflightchainsinkidneydiseaseevenin
theabsenceofmultiplemyeloma(monoclonalgammopathyofrenal
signicance[MGRS])98Presenceofpers

---

### Chunk 26/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.500

tospecialistkidneycareservicesinthecircumstanceslistedinFigure48.SpecialconsiderationsPediatricconsiderations.PracticePoint5.1.2:Referchildrenandadolescentstospecialistkidneycareservicesinthefollowingcircumstances:anACRof30mg/g(3mg/mmol)oraPCRof200mg/g(20mg/mmol)ormore,conrmedonarepeatrstmorningvoidsample,whenwellandnotduringmenstruation,persistenthematuria,anysustaineddecreaseineGFR,hypertension,kidneyoutowobstructionoranomaliesofthekidneyandurinarytract,knownorsuspectedCKD,orrecurrenturinarytractinfection.5.2SymptomsinCKD5.2.1Prevalenceandseverityofsymptoms[Norecommendationsandpracticepoints]5.2.2IdenticationandassessmentofsymptomsPracticePoint5.2.2.1:AskpeoplewithprogressiveCKDabouturemicsymptoms(e.g.,reducedappetite,nausea,andleveloffatigue/lethargy)ateachconsultationusingastandardizedvalidatedassessmentofuremicsymptomstool.

---

### Chunk 27/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.500

.Diagnosticaccuracyofpoint-of-caretestsfordetectingalbuminuria:a
systematicreviewandmeta-analysis.AnnIntMed.2014;160:550‚Äì557.318SoFtablesSupplementaryTableS5SearchdateJuly2022
Citationsscreened/includedstudies2184/65
SupplementaryFigureS5Chapter2RiskassessmentinpeoplewithCKDClinicalquestionArekidneyfailurepredictionequationsgoodpredictorsofprogression,kidneyfailure,orend-stagerenaldisease?PopulationAdults,children,andyoungpeoplewithCKDG1-G5PredictorKidneyfailureriskequations(e.g.,Tangriequation[KidneyFailureRiskEquation])OutcomesPrognosticperformance:Calibration(goodnessofmeasures,e.g.,R2,Brierscore,andHosmer-Lemeshowtest)Discrimination(e.g.,sensitivity/specicity;areaunderthecurve[AUC]fromreceiveroperatingcharacteristic[ROC]andareaunderthereceiveroperatingcharacteristiccurve[AUROC];C-statistic)StudydesignSystematicreview
ExistingsystematicreviewNationalInstituteforHealthandCareExcellence.Evidencereviewforthebestcombinationofmeasurestoidentifyincreasedriskofprogressioninadults,childr

---

### Chunk 28/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.499

adultswithadvancedchronickidneydisease:resultsfromthe
EQUALstudy.JRenNutr.2018;28:165‚Äì174.876.LimSL,LinXH,DanielsL.Seven-pointsubjectiveglobalassessmentis
moretimesensitivethanconventionalsubjectiveglobalassessmentin
detectingnutritionchanges.JPENJParenterEnteralNutr.2016;40:966‚Äì972.877.GraterolTorresF,MolinaM,Soler-MajoralJ,etal.Evolvingconceptson
inammatorybiomarkersandmalnutritioninchronickidneydisease.Nutrients.2022;14:4297.878.PawlaczykW,RogowskiL,KowalskaJ,etal.Assessmentofthenutritional
statusandqualityoflifeinchronickidneydiseaseandkidneytransplant
patients:acomparativeanalysis.Nutrients.2022;14:4814.879.Epping-JordanJE,PruittSD,BengoaR,etal.Improvingthequalityof
healthcareforchronicconditions.QualSafHealthCare.2004;13:299‚Äì305.880.NicollR,RobertsonL,GemmellE,etal.Modelsofcareforchronickidneydisease:asystematicreview.Nephrology(Carlton).2018;23:389‚Äì396.881.CollisterD,PyneL,CunninghamJ,etal.Multidisciplinarychronickidneydiseaseclinicpractices:ascopingreview.CanJKidneyHea

---

### Chunk 29/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.497

hohavemetabolicdisordersandareonaverylow‚Äìproteindiet,acystatinC‚Äìbasedequationislikelymoreappropriate.1.3EvaluationofalbuminuriaAlbuminuriareferstoabnormallossofalbuminintheurine(urineACR$30mg/gor$3mg/mmol).Albuminisonetypeofplasmaproteinfoundintheurineinnormalsubjectsand
inlargerquantityinpeoplewithkidneydisease.IntheKDIGO
2012ClinicalPracticeGuidelinefortheEvaluationand
ManagementofChronicKidneyDisease,1clinicalterminologywaschangedtofocusonalbuminuriaratherthanproteinuria
asalbuministheprincipalcomponentofurinaryproteininmostkidneydiseases.Epidemiologicdatademonstrateastrongrelationshipbetweenthequantityofurinealbuminwithboth
kidneyandCVDriskandobservedCVDevenatverylow
levels,andassaystomeasurealbuminaremorepreciseand
sensitivethanassaystomeasureurineprotein.Wereferto
albuminuriaorurinealbuminwhendiscussinggeneral
conceptsandwillrefereithertototalprotein,albumin,orother
specicproteinswhendiscussingthatparameterspecically.1.3.1GuidanceforphysiciansandotherhealthcareprovidersPrac

---

### Chunk 30/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.495

g.ClinNephrol.1999;51:220‚Äì227.366.ParsonsMP,NewmanDJ,NewallRG,etal.Validationofapoint-of-care
assayfortheurinaryalbumin:creatinineratio.ClinChem.1999;45:414‚Äì417.367.PendersJ,FiersT,DelangheJR.Quantitativeevaluationofurinalysistest
strips.ClinChem.2002;48:2236‚Äì2241.368.PoulsenPL,MogensenCE.Clinicalevaluationofatestforimmediateand
quantitativedeterminationofurinaryalbumin-to-creatinineratio.Abrief
report.DiabetesCare.1998;21:97‚Äì98.369.PugiaMJ,LottJA,KajimaJ,etal.Screeningschoolchildrenfor
albuminuria,proteinuriaandoccultbloodwithdipsticks.ClinChemLabMed.1999;37:149‚Äì157.370.SakaiN,FuchigamiH,IshizukaT,etal.Relationshipbetweena
urineprotein-to-creatinineratioof150mg/gramcreatinineanddipstickgradeinthehealthcheckup:substantialnumberoffalse-
negativeresultsforchronickidneydisease.TokaiJExpClinMed.2019;44:118‚Äì123.371.SalinasM,L√≥pez-Garrig√≥sM,FloresE,etal.Urinaryalbuminstripassay
asascreeningtesttoreplacequantitativetechnologyincertain
conditions.ClinChemLabMed.2018;57:204‚Äì209.

---

